Roche Pharmaceuticals Confirms Organovo 3D Bioprinting Results

San Diego-based 3D bioprinting company Organovo made a breakthrough in November of last year when their researchers successfully tested the effects of a toxic drug (good ol’ toxic Tylenol) on an array of 3D printed liver cells. Though their internal studies revealed that 3D printed liver cells react similarly to Acetaminophen the way that they would in the natural environment of the human body, these results had yet to be verified by outside researchers. In January, the company first sent its 3D printed liver assays to an outside lab, that of biotech giant Roche Pharmaceutical, for study. Organovo has finally heard back from their research partner and the results are quite positive.
(...weiter auf 3dprintingindustry.com)